About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, December 22nd, 2017

The QualityStocks
Daily Stock List


Broadway Gold Mining Ltd. (BDWYF)

Streetwise Reports, Stockhouse, Barchart, and InvestorsHub reported on Broadway Gold Mining Ltd. (BDWYF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A resource company, Broadway Gold Mining Ltd. centers on development-stage projects with advanced exploration potential. The Company owns a 100 percent interest in the Madison copper-gold project in the Butte-Anaconda mining region of Montana. Broadway Gold Mining’s shares trade on the OTC Markets Group’s OTCQB. The Company has its corporate office in Vancouver, British Columbia.

The Madison copper-gold project is permitted for exploration. It contains a past-producing underground mine that Broadway Gold Mining has refurbished. The Company is expanding known copper and gold zones, which remain open for development in the mine's perimeter.

Broadway’s exploration program has identified new anomalies across its wide-ranging land package. These provide drill targets believed to be associated with large-scale porphyry mineralization.

The Company identified copper-gold porphyry targets at Madison in 2017, supported by a newly assembled geological model. Phase I and II drilling this year returned high-grade gold and copper intersections from shallower skarn zones. Many high-priority targets, including porphyry, will be the emphasis of Phase III drilling.

In October, Broadway Gold Mining announced the discovery of a new latite porphyry zone of mineralization at its Madison project in the legendary Butte-Anaconda mining region of Montana.

Mr. Duane Parnham, Broadway Gold Mining’s President and Chief Executive Officer, said, "Broadway's technical team has successfully delivered on a fourth major milestone worthy of additional testing by discovering a porphyry system underlying the shallower skarn zones, which were mined in the past and expanded in our recent drilling. Although indications suggest a typical copper porphyry alteration system is present, this new mineralization discovered at Madison exhibits similar characteristics to the latite porphyry hosted at Barrick's Golden Sunlight Mine (GSM) located 36 kilometers away in Whitehall, Montana."

Last month, Broadway Gold Mining announced that, as a result of its recent porphyry discovery, it has staked additional ground to cover favorable geological and geophysical targets in the area of its 100 percent-owned Madison copper-gold project.

The new claims are contiguous to the south of the Company’s active exploration area. The new claims extend the current Madison property footprint to 2,514 acres.

Broadway’s Phase III drilling program continues. The Company is fully funded for completion of the program. Deeper geophysical targets from the 2017 survey appear to trend through the original property boundary onto the newly acquired claims.

Broadway Gold Mining Ltd. (BDWYF), closed Friday's trading session at $0.29, up 6.70%, on 20,640 volume with 16 trades. The average volume for the last 60 days is 39,243 and the stock's 52-week low/high is $0.239/$1.29.

Omnitek Engineering Corp. (OMTK)

Marketbeat, FeedBlitz, OTCPicks, and Penny Stock Rumble reported previously on Omnitek Engineering Corp. (OMTK), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Omnitek Engineering Corp. develops and sells proprietary diesel-to-natural gas conversion systems and complementary products. This includes new natural gas engines that use Omnitek’s technology. These provide its global customers with inventive alternative energy and emissions control solutions that are sustainable and affordable. Omnitek Engineering is headquartered in Vista, California.

The Company’s products include New Natural Gas Engines, Engine Specific Diesel-to-Natural Gas (DNG) Engine Conversion Kits, and products for Diesel-to-Natural Gas Engine Conversions, Engine Management System (EMS) and Components, EFI for V-Twin Motorcycles and Small Engines, and Hydrogen Internal Combustion Engines. The DNG system has established Omnitek Engineering as a leader in the industry.

Omnitek’s conversion technology provides fleets with a 100 percent dedicated natural gas engine at a fraction of the cost of a new natural gas engine. Omnitek Engineering’s commitment is to be at the forefront of technology. Furthermore, the Company’s commitment is to develop innovative solutions that redefine the future of low emissions, energy independence, and transportation.

The Company has established a strategic alliance with LKQ Corp. to produce "drop-in" natural gas engines at Omnitek Engineering’s facility in Monterrey, Mexico, initially for the widely-used Mercedes OM904 and OM906 engines. LKQ is a foremost provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles.

Omnitek Engineering has received worldwide certification for its patented fuel rail technology. This is based on tests conducted by an independent agency and standards sanctioned by the United Nations Economic Commission for Europe, specifically UN ECE R110.

Omnitek will participate in a $1.5 million grant study with its partner Olson-Ecologic Testing Laboratories (Fullerton, California). The study is to demonstrate its clean natural gas engine technology for off-road heavy duty construction vehicle applications in the greater Los Angeles, California area.

Omnitek will develop an 18-liter Caterpillar natural gas engine capable of operating on CNG, LNG, or low-carbon intensive renewable biogas (R-CNG) through using its patented diesel-to-natural gas engine conversion technology. Olson-Ecologic Engine Testing Laboratories will serve as project manager.

This month, Omnitek Engineering announced that it received a contract to develop a heavy-duty 12-liter propane engine for Class 8 trucks and certify the engine to EURO 6 emissions standards. The 12-liter 360 hp propane (LPG) engine complements Omnitek’s current development of a 13-liter 450 hp heavy-duty natural gas engine for Class 8 truck applications to meet EURO 6 emissions.

Omnitek Engineering Corp. (OMTK), closed Friday's trading session at $0.08, up 14.29%, on 10,250 volume with 3 trades. The average volume for the last 60 days is 14,762 and the stock's 52-week low/high is $0.054/$0.225.

Progressive Care, Inc. (RXMD)

OTC Markets and Investors Hangout reported on Progressive Care, Inc. (RXMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Progressive Care, Inc., via its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization. The Company is moving ahead in its work to grow the Company by expanding its facility, adding new locations, acquiring operating pharmacies, and further developing its present business lines. Progressive Care has its corporate headquarters in North Miami Beach, Florida.

The Company is a provider of prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long term care facilities. It is also a provider of administration and practice management, utilization management, quality assurance, EHR Implementation, billing and coding, as well as health practice risk management.

Progressive Care owns PharmCo LLC. PharmCo formed in 2005 as a Florida Limited Liability Corporation with the aim of becoming a first-class pharmacy in the South Florida community. PharmCo has developed into a health services company that centers on the provision of prescription pharmaceuticals.

PharmCo’s compounding department specializes in formularies such as non-narcotic topical pain creams, wound care creams, scar gels, and hormone replacement therapies. In addition, it offers EnovaRx, which are Food and Drug Administration (FDA) approved manufactured pain creams. These are promptly available with a prescription.

Furthermore PharmCo prepares psoriasis creams, wellness vitamins, weight loss formulations and holistic capsules that are 100 percent Kosher and Halal certified. PharmCo has attained much of its growth by way of targeted marketing to new doctors' offices and clinics.

Progressive Care opened Smart Medical Alliance, Inc. on September 1, 2016. It opened Smart Medical to assist healthcare providers with navigating the complex risk management environment of their insurance network contracts.

Smart Medical Alliance provides management and support services to doctors and administrators under capitated and fee-for-services insurance contracts. Smart Medical Alliance is the premier Outsourced Clinical and Management Services Partner.

Last month, Progressive Care announced greater than $1.7 million in net revenues on more than 21,000 prescriptions filled in October 2017. Prescriptions filled increased by close to 15 percent over the same month the year prior and by 5 percent over the last record setting month in August of 2016. This is a 24 percent increase over September 2017.

Moreover, Progressive Care announced last week more than $1.7 million in net revenues on close to 21,000 prescriptions filled in November 2017. Prescriptions filled increased by almost 13 percent over the same month the year prior. Additionally, the Company filled more than $400,000 worth of prescriptions for 340B entities, generating fees to the pharmacy of just over $17,000.

Progressive Care, Inc. (RXMD), closed Friday's trading session at $0.016, up 3.90%, on 1,001,051 volume with 29 trades. The average volume for the last 60 days is 1,007,303 and the stock's 52-week low/high is $0.01/$0.0329.

Humanigen, Inc. (HGEN)

AmigoBulls, Barchart, TradingView, Investopedia, InvestorsHub, OTC Markets, Investors Hangout, and Financial Times reported on Humanigen, Inc. (HGEN), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Humanigen, Inc. focuses on advancing medicines for patients with neglected and rare diseases by way of unique, accelerated business models. Lead compounds in the Company’s portfolio include benznidazole, and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. OTCQB-listed, Humanigen is based in Brisbane, California.

Humanigen pursues innovative science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Benznidazole is for the potential treatment of Chagas disease in the U.S. Chagas disease is a parasitic infection caused by a protozoan organism named Trypanosoma cruzi, which affects millions of people primarily in rural areas of Mexico, Central and South America.

Lenzilumab has potential for treatment of various rare diseases. This includes hematologic cancers such as chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

Lenzilumab is a Humaneered® recombinant monoclonal antibody. It neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a critical cytokine that propels the growth of certain hematologic malignancies.

Ifabotuzumab is a first-in-class, monoclonal antibody. It targets the EphA3 receptor tyrosine kinase created using Humanigen's proprietary Humaneered® technology.

Humanigen announced in August 2017 that it completed enrolment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is an important part of its planned New Drug Application (NDA) package to the U.S. Food and Drug Administration (FDA) in the 505(b)(2) development program for benznidazole as a potential treatment for Chagas disease. The study’s principal objective is to characterize the pharmacokinetic profile of benznidazole.

Humanigen continues to enrol patients in its Phase 1 study of lenzilumab for the treatment of chronic myelomonocytic leukemia (CMML), a rare hematologic cancer. Interim data is expected in the first half of 2018.

The other key asset in the Company’s monoclonal antibody portfolio, ifabotuzumab, has been dosed in the first patient in an investigator-sponsored phase 0/1 radio-labeled imaging trial in glioblastoma multiforme (GBM). GBM is a particularly aggressive and deadly brain cancer.

Yesterday, Humanigen announced it entered into definitive agreements with its lenders to, among other things, exchange the entire balance of roughly $16.3 million in term loans for common stock of Humanigen. The expectation is that the transactions will close in Q1 2018 subject to the satisfaction of certain conditions contained in the definitive agreements.

In addition, the Company will receive a new $3 million investment from an affiliate of Black Horse Capital, one of the lenders, to fund the Company and its transformational new strategy of developing the monoclonal antibodies lenzilumab and ifabotuzumab in the fast-growing areas of immunotherapy and oncology.

Humanigen, Inc. (HGEN), closed Friday's trading session at $0.3501, up 105.94%, on 97,540 volume with 62 trades. The average volume for the last 60 days is 24,908 and the stock's 52-week low/high is $0.125/$4.50.

Diego Pellicer Worldwide, Inc. (DPWW)

MarketWatch reported on Diego Pellicer Worldwide, Inc. (DPWW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Diego Pellicer Worldwide, Inc. is a real estate and consumer retail development company. It centers on developing the Company as the world’s first "premium" marijuana brand. Its tenants are stand-alone, independent businesses and Diego Pellicer Worldwide has no ownership in them. Diego Pellicer Worldwide is headquartered in Seattle, Washington. The Company lists on the OTC Markets Group’s OTCQB.

Through the development and acquisition of premium, legally compliant real estate locations for cannabis growers and retailers, Diego Pellicer provides a best-in-class platform for new business growth in the cannabis industry.

The Company does not grow or sell marijuana or marijuana infused products. It leases legally compliant locations for growing, retailing, or the medical dispensing of marijuana.

Fundamentally, Diego Pellicer is where responsible marijuana connoisseurs and sommeliers convene to explore the world of premium marijuana. The Company is the international leader in property acquisitions and leasing in the developing cannabis space.

Diego Pellicer’s initial focus is to acquire and develop legally compliant real estate locations for the purposes of leasing them to State licensed companies in the cannabis industry. Its initial revenues originate from leasing real estate and selling non-cannabis related products.

Diego Pellicer participates in the profit of café operations of non-infused products; participates in the profit of ancillary products, including branded apparel; and in some instances, it signs contracts with its tenants, with the right to acquire at its discretion. The Company has secured many premier locations in Colorado, Washington, and Oregon.

Diego Pellicer Worldwide has leased two facilities to grow operators in Denver, Colorado. These grow facilities are licensed for medical and recreational cannabis. The facilities are more than 30,000 sq. ft.

Its first flagship store tenant, Diego Pellicer Washington (3,000 sq. ft. space) passed its final inspection for retail marijuana sales and commenced operations in Q4 of 2016. This flagship store features high-end cannabis products and accessories.

Earlier this month, Diego Pellicer Worldwide announced that it has partnered with world-class architect Mr. Michael Rotondi, FAIA, and creative trailblazer Ms. Jill Savini to develop retail prototypes and unique branding for future store locations. Mr. Rotondi has made a major impact in the industry as an architecture educator at Arizona State University and the Southern California Institute of Architecture, of which he was a Co-Founder and later became its second Director. His Los Angeles, California-based firm, RoTo Architects, is the official architecture agency of record for Diego Pellicer Worldwide.

Ms. Savini specializes in working across all mediums on branding, packaging, digital, and retail. As head of corporate branding for Diego Pellicer Worldwide, she is responsible for ensuring a consistent look and branding across retail locations.

Diego Pellicer Worldwide, Inc. (DPWW), closed Friday's trading session at $0.04, up 13.31%, on 708,590 volume with 46 trades. The average volume for the last 60 days is 510,073 and the stock's 52-week low/high is $0.0155/$0.39.

ForeverGreen Worldwide Corporation (FVRG)

InvestorsHub, 4-Traders, MarketWatch, OTC Markets, and MicroCapDaily reported on ForeverGreen Worldwide Corporation (FVRG), and we also report on the Company, here at the QualityStocks Daily Newsletter.

ForeverGreen Worldwide Corporation is an international direct marketing company and provider of health and wellness products. The Company develops, manufactures, and distributes an extensive line of all-natural whole foods and products to North America, Australia, Europe, Asia, and South America.

ForeverGreen Worldwide is headquartered in Lindon, Utah. The Company was established in May of 2004 by Chief Executive Officer and Chairman Mr. Ron Williams. ForeverGreen Worldwide lists on the OTC Markets Group’s OTCQB.

The Company’s products include its new global Xpress offering Prodigy-5™, featuring the exclusive TransArmor™ Nutrient Technology. In addition, its products include PowerStrips™, SolarStrips™, with industry exclusive marine phytoplankton and BeautyStrips™.

ForeverGreen Worldwide also offers the North American market its weight-management line called Ketopia™, as well as additional weight management products. Furthermore, the Company offers its Pulse-8™ powered L-arginine formula for cardiovascular health.

ForeverGreen Worldwide announced earlier this year its new wearable technology called CareWear™. The presale of this device, with continuous monitoring from the health application GoHeart, was a limited time offer with a first-time association of use with the Company's nutrition products.

CareWear, in combination with daily use of ForeverGreen nutritional products, is what ForeverGreen Worldwide is positioning as the Total Health Experience, which completes the outside edge of nature, science, products, education and technology formulated in research and development (R&D) of all ForeverGreen’s product offerings.

This past September, ForeverGreen Worldwide announced that Dr. Balamurali Ambati, Ph.D., M.D., and Dr. Adam Saucedo, M.D., were training ForeverGreen Members with a series of presentations in multiple languages. The purpose of the recorded webinar series was to continue ForeverGreen’s streamlined approach of positioning products and to educate Members regarding TransArmor™ Nutrient Technology developed by the doctors, to increase brand awareness, and subsequent Member enrolment.

TransAmor™ Nutrient Technology is patent pending. It was created from four decades of peer-reviewed science. It allows the nutrients in formulated products to be considerably better absorbed by the body.

ForeverGreen Worldwide’s Prodigy-5 is an all-in-one nutritional shot. It features the patent-pending and exclusive TransArmor™ Nutrient Technology for increased absorption. Prodigy-5 provides vitamins, minerals, antioxidants and energy, all in one.

ForeverGreen Worldwide Corporation (FVRG), closed Friday's trading session at $0.09, up 12.50%, on 33,133 volume with 7 trades. The average volume for the last 60 days is 16,637 and the stock's 52-week low/high is $0.08/$0.40.

Lifestyle Delivery Systems, Inc. (LDSYF)

MarketWatch, InvestorsHub, Stockhouse, OTC Markets, and Barchart reported on Lifestyle Delivery Systems, Inc. (LDSYF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lifestyle Delivery Systems, Inc.’s filmstrip technologies produce an oral delivery system. This system can be utilized for energy elixirs, herbal remedies, and a smokeless alternative option to medical and recreational users of cannabis. Lifestyle Delivery Systems’ (LDS) technology produces infused strips, which are similar to breath strips. These strips are a safer, healthier option to smoking. Additionally, they are a new way to accurately meter the dosage and assure the purity of the product. Lifestyle Delivery Systems is based in Vancouver, British Columbia.

Furthermore, the Company has entered into management services agreements with NHMC, Inc. and CSPA Group, Inc. LDS has started its direct involvement in the growing of medicinal ingredients for, and the manufacturing of, its products.

Its products and ingredients (from seed to sale) will be tested for quality and composition throughout the formulation and production processes. This results in a delivery system that is safe, consistent, as well as effective.

The Company’s CannaStrips™ are cannabis infused oral strips. They provide an exact and controlled dosage of cannabis. They do so without the health risks associated with smoking or potential chemical inhalation associated with some smokeless inhalers.

With LDS’ patent pending delivery system technology, the consumer is able to feel the effects of the Company’s CannaStrips™ in 90 seconds or less, depending on dosage. The design of CannaStrips™ is to provide patients with non-intrusive, non-smoking alternatives.

This week, LDS announced that it signed agreements with a California corporation, which holds a Permit and CUP for volatile extraction and manufacturing in Adelanto, California. With these agreements, R2T Manufacturing, Inc. will license proprietary and patent pending technologies from Lifestyle Delivery Systems and contract for consulting services from LDS Scientific. Inc. The Company intention is to construct a new 20,000 square foot facility for the Licensee's operations.

Today, LDS announced that on December 21, 2017, the Manufactured Cannabis Safety Branch of the California Department of Public Health issued CSPA Group, (CSPA) a Temporary Category M Type 7 Manufacturing with Volatile Solvents License. It will be effective January 1, 2018 through April 30, 2018. During this time, the California Department of Public Health will review CSPA's application and corresponding municipal permits and documentation for a permanent license.

Mr. Brad Eckenweiler, LDS’ Chief Executive Officer, stated, "There are milestones and then there are milestones. This license marks the beginning of the most significant milestone yet in the development of the CannaStrips™ project. On January 1, 2018 for the first time the LDS CannaStrips™ technology with the CSPA Group, Inc. licensee and LDS Scientific, Inc. consulting will be producing a product for patients that is safe, free of contaminates, with accurate dosage, delivering consistent results and licensed by the State of California.”

Lifestyle Delivery Systems, Inc. (LDSYF), closed Friday's trading session at $0.6003, up 11.83%, on 525,112 volume with 198 trades. The average volume for the last 60 days is 136,650 and the stock's 52-week low/high is $0.267/$0.6695.


The QualityStocks
Company Corner


Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF)

The QualityStocks Daily Newsletter would like to spotlight Victory Square Technologies Inc. (VSQTF). Today, Victory Square Technologies Inc. closed trading at $2.80, off by 3.45%, on 487,069 volume with 719 trades. The stock’s average daily volume over the past 60 days is 101,408 and its 52-week low/high is $0.298/$3.32.

Based on evidence that cannabinoids and opioids can work in synergy to moderate pain, Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) and its research arm, Cannevert Therapeutics Ltd., intend to boost actions of opioid analgesics with a specific strain of cannabis. A recent article highlights the company’s approach in developing quality strains, stating, “Veritas Pharma employs a scientific approach to support medical cannabis claims and is intent on developing and commercializing the most effective strains of cannabis for medical use. To view the full article, visit: http://cnw.fm/YHz7P

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) is a venture builder that creates, funds and empowers entrepreneurs working in the fields of blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources, and other forms of operational support to help them scale internationally.

Victory Square has made multiple early partnerships and investments in the blockchain space. Approximately three years ago the company incubated and invested in BTL Group, which is now a $150 million dollar TSX-listed company offering blockchain solutions across multiple industries with particular focus on the finance, energy and gaming sectors. BTL's showcase product – Interbit – is a blockchain platform that facilitates the rapid development of business applications that dramatically improve efficiency. Some of the world's largest institutions are using Interbit to explore new opportunities on private blockchains.

A new social sports betting platform to be developed by Victory Square's wholly owned subsidiary, FansUnite Media Inc. As a social sports data platform, FansUnite relies on robust data to allow members of its community to engage with like-minded individuals by collaborating, discussing, and predicting the winners of sporting events with a free virtual currency. The integration of blockchain technology into FansUnite's social sports data platform could also lead to blockchain initiatives developed by other divisions and subsidiaries of Victory Square.

Integral to the FansUnite platform is the introduction of FAN Tokens, an in-game currency purchased with the cryptocurrency Ethereum that token holders can use to place wagers. FansUnite members will be able to earn FAN Tokens through participation in any number of networking effects identified in the company's Bounty program.

"Blockchain technology and the inherent security it provides will enable us to push every envelope we can to build the most dynamic and responsive social sports betting platform," said Darius Eghdami, Co-Founder and Chief Executive Officer of FansUnite. "The opportunity to secure data through Blockchain certainly appeals to the accountant in me and we are confident it will become the gold standard among sports betting sites around the world."

Company subsidiary Victory Square Health Inc., which serves as the venture arm dedicated to companies focused on the development of solutions in personalized health technologies, has also invested in Personalized Biomarkers Inc. (PBI). PBI develops test kits that reliably predict the expected response to a number of therapies prior to prescription, with an initial focus on diabetes. Within this field, five potential biomarkers have been identified, allowing PBI to enter a $4 billion market opportunity.

"We are excited for the opportunity to partner with Personalized Biomarkers as they have correctly identified a massive market opportunity, and have formed an exceptional team of industry leaders," said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. "This is another investment that is fully aligned with our newly created subsidiary, and one we expect to significantly impact the landscape of personalized medicine."

A partnership with Insight Diagnostics Inc., also through Victory Square Health, will focus on the development of a personalized diagnostic solution for the improved management and prevention of Type II diabetes.

The company's investment in V2 Games, a development and publishing studio of high-quality mobile games, is another example of incubating great ideas. V2 Games is well known for its successful launch of PAC-MAN Bounce and Beast Brawlers, two of the company's releases that are capturing the gaming world by the millions of downloads.

In a move designed to strengthen its presence in film and entertainment, Victory Square has acquired a 40 percent equity stake in United Film Fund II, LLC, which is producing three major motion pictures in 2017 and 2018 including "What They Had," starring two-time Academy Award winner Hilary Swank.

"This kind of investment in entertainment and film represents a major plank for our Company going forward and we consider ourselves fortunate to have the opportunity to acquire this 40% stake in the Film Fund," said Tejani, who has launched more than 40 startups in 21 countries that employ hundreds of people and generate more than $100 million in annual revenues. "We believe it's another strong initiative in film production for us and our stakeholders," he added.

Victory Square has strategically positioned itself in the legal cannabis industry through an investment in Tantalus Labs, a Canadian-based cannabis cultivation company. Tantalus Labs optimizes plant health and sustainable cultivation by using a unique, environmentally controlled greenhouse engineered specifically for growing cannabis. Called a "SunLab," the greenhouse takes 90 percent less electricity, uses filtered rainwater, and cools the growing environment to prevent stagnant moisture, recycling the air every 7 minutes to achieve maximum airflow.

Victory Square and its leadership team have seamlessly transitioned from its former identity as Fantasy 6 Sports Inc, a company focused solely on fantasy sports, mobile gaming and immersive sports, to a strategic technology company that creates, funds and successfully executes leading-edge ideas. A long-time technology entrepreneur and advocate of the industry, Tejani received the Person-of-the-Year Award at the 2017 Technology Impact Awards in British Columbia, a hallmark award category that recognizes betterment of the tech industry through leadership and philanthropic or enterprise skills and talents. Tejani has pledged to match up to $1 million in donated funds to be shared by a number of Canadian endeavors aimed at education and child-safe projects.

"These are exciting and important steps in the evolution and growth of our Company, and which properly and fully align with our strategic plan focusing on our core competencies in Blockchain Technology, Artificial Intelligence, Gaming, Personalized Health, Film and Virtual, Augmented and Mixed Reality," said Tejani. "We're spurred on by the success we have had in building on our original forays into fantasy sports, mobile gaming and immersive sports. In addition, we are energized by our most recent initiatives in sports, personalized health and entertainment and the confidence being shown by our shareholders in the dynamic direction of the Company."

Victory Square Technologies and its management team believe innovation, incubation of excellent ideas and social responsibility are at the core of its growing success. Disclaimer

Victory Square Technologies Inc. Blog

Victory Square Technologies Inc. News:

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) to Leverage Unique Compound Synergies for Pain Moderation

Victory Square Technologies Introduces an Incubated Portfolio Company, Blockchain Assembly, a Blockchain Investment & Cryptocurrency Advisory Firm

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) is “One to Watch”

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.69, off by 1.74%, on 221,445 volume with 263 trades. The stock’s average daily volume over the past 60 days is 382,565 and its 52-week low/high is $0.225/$2.13.

Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017 Marijuana Business Conference & Expo (MJBizCon) in Las Vegas, Lexaria’s chairman and CEO Chris Bunka offered some thoughts on the future of cannabis during an interview with The Street at the LD Micro conference in Los Angeles last week.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Uptick Newswire “Stock Day” Interviews CEO of Lexaria on Cannabis Related Products and Recent Bioscience Patents

Lexaria Bioscience Receives U.S. Patent Award for its DehydraTECH(tm) Delivery of THC, NSAIDs, Nicotine and Vitamins

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.83, off by 9.78%, on 623,256 volume with 395 trades. The stock’s average daily volume over the past 60 days is 219,189 and its 52-week low/high is $0.40/$2.75.

NetworkNewsWire, a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the audio version of the press release titled “Top-Rated Cryptocurrency Podcast, ‘Bad Crypto Podcast’ Features Interview with ChineseInvestors.com, Inc.'s CEO, Warren Wang” recently issued by ChineseInvestors.com, Inc. (OTC:CIIX).
To hear the NetworkNewsAudio version, visit http://nnw.fm/Oz7CQ
To read the original press release, visit http://nnw.fm/iM8jR

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

NetworkNewsAudio Covers ChineseInvestors.com’s Release on Recent Interview on Top-Rated Cryptocurrency Podcast

Top-Rated Cryptocurrency Podcast, "Bad Crypto Podcast" Features Interview with ChineseInvestors.com, Inc.'s CEO, Warren Wang

ChineseInvestors.com, Inc. Announces its Plan to Spin Off its Wholly-owned Foreign Entity, CBD Biotechnology Co. Ltd., and its Wholly-owned Subsidiary, ChineseHempOil.com, Inc. to Allow the Company to Focus on its New Cryptocurrency Division and its Core Financial Education Business

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.045, up 28.57%, on 150,734 volume with 18 trades. The stock’s average daily volume over the past 60 days is 238,331 and its 52-week low/high is $0.01/$0.33.

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

Skinvisible Announces Proposed Merger with Quoin Pharmaceuticals

New Skinvisible, Inc. (SKVI) Subsidiary Signs Exclusive License Agreement to Distribute Its Topical Cannabis Products in the USA

Skinvisible, Inc. (SKVI) Engages NetworkNewsWire for Corporate Communications Solutions

Petrogress, Inc. (PGAS)

The QualityStocks Daily Newsletter would like to spotlight Petrogress, Inc. (PGAS). Today, Petrogress, Inc. closed trading at $0.04, up 24.61%, on 959,571 volume with 43 trades. The stock’s average daily volume over the past 60 days is 436,761, and its 52-week low/high is $0.0161/$0.072.

Petrogress, Inc. (PGAS) founded in 2009, owns and operates a fleet of tankers from its base in the historic Port of Piraeus, Greece, through a series of Marshall Islands subsidiaries. The company is an international merchant of petroleum products which includes reliably marketing and trading crude oil, distillates, and refined products off the coast of West Africa. The company also operates service and shipping facilities at the Port of Limassol in Cyprus and the Port of Tema, Greater Accra, in Ghana. It is actively seeking expansion opportunities, including in operating and developing natural gas production and transmission facilities along with LNG processing in the U.S., refinery operations in north and west Africa, and the transport and sales of LNG in Europe.

Petrogress has created a diversified revenue stream, giving it a significant advantage over similar companies working in the oil and gas shipping arena. A case in point is the recent formation of "PG Cypyard & Offshore Service Terminal Ltd. ("Cypyard"), through the company's wholly owned subsidiary, Petrogress Int'l, LLC. Cypyard is concluding negotiations for an operations and management agreement covering ports in Hellenic Cyprus, including the Port of Limassol, directly with the Cyprus Ports Authority. Current plans include a long-term lease with renewal options covering all in-place port facilities, including floating dock and dry dock areas, with cranes and scaffolding, construction and repair workshops and storage, and complete on-site administrative and office space.

"I think the opportunities there are great, and dealing directly with partners in government has numerous benefits," said Christos P. Traios, president of Petrogress Inc. in a news release announcing the venture. The recent appointment of two industry experts to the Petrogress Advisory Board is expected to help the company capitalize on future growth opportunities while simultaneously developing a comprehensive U.S. and international lobbying and government outreach program to facilitate business plans in the U.S., European Union and Africa.

Additional Petrogress Inc. subsidiaries are:

  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Oil & Gas Energy Inc., which has expansion plans through a supply of liquified natural gas located in the oil fields of Texas with an eye toward exporting LNG to Mediterranean markets.

Petrogress continues to "adjust its sails" in order to meet new challenges. Opportunities include upstream oil resources and exploration, the addition of more product fleet carriers, downstream movement of petroleum products from refineries to finished sales, and sea transportation of liquified natural gas. A closely followed economist, Jim O'Neill, states that oil prices could spike more than 25% in the next year. O'Neill, now an economics professor at the University of Manchester, says the market is finally waking up to the fact that global economic growth is gaining momentum and likely expanding at 4 percent or higher. That means there will be more demand for oil, the article states, which translates into brighter days ahead for companies like Petrogress. Disclaimer

Petrogress, Inc. Company Blog

Petrogress, Inc. News:

Petrogress, Inc. Announces Joint Venture with International Marine Fleet & Offshore Support Provider

NetworkNewsWire Releases Exclusive Audio Interview with Petrogress Inc. (PGAS)

Petrogress, Inc. (PGAS) is “One to Watch”

Zinc One Resources, Inc. (TSX-V:Z) (OTC:ZZZOF) (FSE:RH33)

The QualityStocks Daily Newsletter would like to spotlight Zinc One Resources, Inc. (ZZZOF). Today, Zinc One Resources, Inc. closed trading at $0.33, up 1.54%, on 131,611 volume with 26 trades. The stock’s average daily volume over the past 60 days is 60,323 and its 52-week low/high is $0.011/$0.81.

Zinc One Resources, Inc. (TSX-V: Z) (OTC: ZZZOF) (FSE: RH33) is a Vancouver, Canada-based company focused on the acquisition, exploration and development of prospective and advanced zinc projects in mining friendly jurisdictions. Zinc One's key assets are the Bongará Zinc Mine and Charlotte-Bongará Zinc-Oxide Project in north-central Peru. Historical production of the Bongará Mine, which was mined from 2007-2008 until a fall in zinc prices shut it down, revealed greater than 20 percent zinc grades and recoveries over 90 percent, all from surface mining. Bongará's high grade zinc mineralization is considered a rare situation and one that Zinc One management is poised to explore further. The neighboring Charlotte-Bongará Zinc-Oxide Project has multiple at-surface, high-grade drill intercepts providing numerous drill targets.

Zinc One controls both zinc-oxide mine projects, making it the first time a single operator has been in control of the two locations, giving the company a unique opportunity to delineate a substantial high-grade, zinc-oxide resource along a 4 kilometres-long trend. A previous operator produced 55.1 million pounds of zinc, running at 358 tonnes a day. Zinc One has access to all data and technical work dating back to the 1990s and controls a third zinc prospect located in central Peru as part of its portfolio.

The company has also received approval from Peru's Ministry of Energy and Mines to suspend the mine closure at the Bongará location, which allows Zinc One to utilize the current Environmental Impact Assessment attached to the project for current and future permitting. This critical approval allows the company to take another important step forward in its plans to reopen production at the Bongará zinc-oxide project. Zinc One's project locations involve open pit/surface mining, requiring less infrastructure and a much better cost ratio than traditional underground mines.

Zinc One is managed by a proven team of exploration geologists and engineers with extensive experience in constructing and operating successful mining operations. The company's business strategy includes restarting production at the Bongará Zinc-Oxide Mine with exploration of targets along a 6-kilometer strike as well as exploring the Charlotte Bongará Zinc-Oxide Project.

World stockpiles of zinc are at multiyear lows while demand continues to be strong. In 2016, zinc demand became greater than the available supply for the first time in a decade. Zinc is essential for rustproofing steel and is used in a variety of infrastructures. It's also used to produce batteries, fertilizers, paints, plastics, cosmetics and multivitamins. The International Zinc Association estimates that zinc could save the world over $300 billion annually in direct corrosion costs and another $300 billion annually in indirect costs. Zinc is an invaluable base metal and a strategic priority for many industries. Disclaimer

Zinc One Resources, Inc. Blog

Zinc One Resources, Inc. News:

NetworkNewsWire Announces Publication Detailing Strong Demand in Global Zinc Market

NetworkNewsWire Announces Publication Highlighting Growing Global Zinc Deficit Amid Rising Demand

NetworkNewsWire Announces Publication Discussing Several Stocks Gearing Up to Fill Zinc Shortage


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.20, up 3.45%, on 350,670 volume with 340 trades. The stock’s average daily volume over the past 60 days is 451,801 and its 52-week low/high is $0.6171/$1.42.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Enters into Agreement to Acquire Leading Medical Cannabis Clinic

ABcann Global Announces Financial Results and Provides Operational Update

NetworkNewsWire Announces Publication on Investment Capital Pouring into Canada's Legal Cannabis Market


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



MarketClub Analysis
(SGLB) +151.80%


(BRZV) +122.22%


(HGEN) +105.94%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251